BioCryst Pharmaceuticals has partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration aims to make the oral, once-daily prophylactic treatment available to patients with hereditary angioedema (HAE) in the Turkish market. Er-Kim, an international pharmaceutical company based in Istanbul, has experience in distributing therapies for rare diseases and will help BioCryst expand the availability of ORLADEYO to patients with unmet needs in Turkey. This partnership marks the sixth global distribution agreement for ORLADEYO.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO® (berotralstat) in Turkey.
“We continue our mission to make ORLADEYO available to as many patients living with hereditary angioedema around the world as possible by partnering with companies that have deep expertise in commercializing rare disease therapies. We are pleased to enter into this agreement with Er-Kim, our sixth global distribution partner for ORLADEYO, as their wealth of experience delivering novel therapies to patients in Turkey makes them the ideal partner to bring our oral, once-daily prophylactic treatment to HAE patients in this important market,” said Charlie Gayer, chief commercial officer of BioCryst.
“We have a shared commitment with BioCryst to bring life-changing medicines to patients living with rare disease and we are excited to deliver ORLADEYO to patients living with HAE in Turkey. Our commercial team is adept at distributing therapies to patients with unmet needs, and we look forward to helping BioCryst achieve its goal of bringing ORLADEYO to patients around the world,” said Cem Zorlular, chief executive officer of Er-Kim.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Er-Kim is an international pharmaceutical company based in Istanbul, Turkey, which specializes in partnering with biopharmaceutical companies to commercialize new products in global markets. With broad experience in a wide range of areas, including rare disease, Er-Kim has worked with its affiliates to deliver more than 70 innovative treatments, including the latest standards of care, to patients around the world.
Source: Bio Space